TETRA DISCOVERY
Tetra Discovery Partners provides consulting services in drug discovery and development. They partner with Universities to commercialize intellectual property and conduct proprietary research on diseases affecting the central nervous system. Their research focuses on developing new treatments for depression and schizophrenia. Severe forms of depression affect 2–5% of the US population, while mood disorders impact 7% of the world’s population and rank among the top ten causes of disability.
TETRA DISCOVERY
Industry:
Biotechnology Health Care Life Science
Founded:
2010-01-01
Address:
Grand Rapids, Michigan, United States
Country:
United States
Website Url:
http://www.tetradiscovery.com
Total Employee:
1+
Status:
Active
Contact:
6164751037
Email Addresses:
[email protected]
Total Funding:
12.45 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS GoDaddy DNS Gravity Forms WP Engine Mimecast
Similar Organizations
Kytopen
Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Current Advisors List
Current Employees Featured
Founder
Investors List
Apjohn ventures
Apjohn ventures investment in Series A - Tetra Discovery
Grand Angels
Grand Angels investment in Series A - Tetra Discovery
Biosciences Research and Commercialization Center (BRCC)
Biosciences Research and Commercialization Center (BRCC) investment in Seed Round - Tetra Discovery
Muskegon Angels
Muskegon Angels investment in Seed Round - Tetra Discovery
J &J Investments
J &J Investments investment in Seed Round - Tetra Discovery
Grand Angels
Grand Angels investment in Seed Round - Tetra Discovery
Michigan.com
Michigan.com investment in Seed Round - Tetra Discovery
Biosciences Research and Commercialization Center (BRCC)
Biosciences Research and Commercialization Center (BRCC) investment in Seed Round - Tetra Discovery
Grand Angels
Grand Angels investment in Seed Round - Tetra Discovery
Michigan Emerging Technology Fund
Michigan Emerging Technology Fund investment in Seed Round - Tetra Discovery
Official Site Inspections
http://www.tetradiscovery.com
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Tetra Discovery"
Tetra Discovery - Crunchbase Company Profile & Funding
Organization. Tetra Discovery . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Tetra Discovery provides consulting …See details»
Tetra Discovery Partners Announces Name Change to Tetra …
Tetra Discovery Partners, a clinical-stage biotechnology company, today announced the company’s name change to Tetra Therapeutics. The name change reflects the company’s …See details»
Tetra Discovery | Company | Mindmaps
Tetra Discovery provides consulting services and research on drug discovery for diseases affecting the central nervous system. Investors. ArcLight Capital Creative Ventures Frontier …See details»
Tetra Discovery Partners | Grand Rapids, MI, USA Startup - Gust
Nov 1, 2010 Tetra Discovery Partners designs drugs to treat memory loss by improving how the brain processes and stores information. This is potentially breakthrough technology that will …See details»
TETRA DISCOVERY PARTNERS LLC - Drug pipelines, Patents, …
Explore TETRA DISCOVERY PARTNERS LLC with its drug pipeline, therapeutic area, technology platform, 9 clinical trials, 7 news, Disease Domain:Nervous System Diseases, …See details»
Organization | Tetra Discovery Partners
Organization Overview. First Clinical Trial. 2015 NCT02648672. First Marketed Drug. None First NDA Approval. None Last Known Activity ... Tetra Discovery Partners Active Ingredients. …See details»
Tetra Therapeutics - Craft
Tetra Therapeutics (also known as Tetra Discovery Partners) is a pharmaceutical company that develops drugs for cognitive impairment treatment. It designs drugs for treating Fragile X …See details»
Tetra Therapeutics - Overview, Competitors, And Employees - Ampliz
Website: www.tetradiscovery.com. Founded: 2010. Employees: 0-10 . Stock Exchange: NA . drug discovery Packaging and Containers Pharmaceuticals . About Tetra Therapeutics . Tetra …See details»
Tetra Therapeutics, a SHIONOGI Group Company | LinkedIn
Tetra Therapeutics, a SHIONOGI Group Company Pharmaceutical Manufacturing Kalamazoo, Michigan 714 followers Follow us at Shionogi Inc. for news about our rare disease research …See details»
Tetra Discovery Partners Initiates Phase 2 Trial of BPN14770 in
Jul 10, 2018 Tetra Discovery has initiated a Phase 2 study of BPN14770 in adults with Fragile X Syndrome, an indication for which BPN14770 has received Orphan Drug Designation from the …See details»
Tetra Therapeutics - Memory Loss Treatment Innovation
Treat cognitive impairment and memory loss by improving how the brain processes and stores information. Working with potentially breakthrough technology, our goal is to improve the …See details»
Tetra - Trout Creek VENTURES
Mar 26, 2016 Tetra Discovery Partners Raises $10 Million through Series A Financing and Two National Institutes of Health Grants. December 19, 2016. Tetra Discovery Partners Announces …See details»
Tetra Discovery Partners - VentureRadar
Tetra Discovery Partners Follow Following Location: USA. Founded in 2011. Privately Held " Tetra is developing a platform of drug products to treat cognitive impairment. Tetra drugs …See details»
Contact Tetra Therapeutics
Contact Tetra Discoveries for clinical trial information for Alzheimer's, Depression, and Brain Injury.See details»
PDE4B Inhibitors For Treating Major Depression | SBIR.gov
Email: [email protected]. Business Contact. Name: MARK GURNEY Phone: (616) 635-0937 Email: [email protected]. Research Institution. ... The World Health …See details»
Tetra Announces $40M to Advance BPN14770 for FXS and …
Dec 19, 2018 Tetra Discovery Partners has signed a multi-part deal that could bring it up to $160 million, plus royalties, from Shionogi & Co, Ltd, a Japanese major research-driven …See details»
Tetra, Shionogi ink $40M pact on PDE4 drug for Alzheimer’s, …
Dec 19, 2018 Tetra Discovery Partners is teaming up with Shionogi to advance its PDE4-targeting drug in Alzheimer’s disease and fragile X syndrome. In return for the rights to the …See details»
Tetra Discovery Partners Initiates Phase 2 Clinical Trial of …
Tetra is conducting the trial with the assistance of the clinical research organization, Syneos Health. “Results of previous Phase 1 studies with BPN14770 in healthy elderly volunteers …See details»
Tetra Discovery Partners and Shionogi & Co., Ltd. Collaborate on ...
Tetra Discovery Partners Contacts: Mark Gurney, Ph.D., Chief Executive Officer Tetra Discovery Partners [email protected] For Media: Joan Kureczka Bioscribe, Inc. …See details»
Tetra Discovery Partners Reaches New $1 Million Strategic …
Oct 5, 2013 Latest Financing to Accelerate Development of Alzheimer’s Drug . Tetra Discovery Partners, a leader in the design of new therapeutics for major neurological conditions based …See details»